These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19581879)

  • 1. A detailed characterization of the adult mouse model of glycogen storage disease Ia.
    Salganik SV; Weinstein DA; Shupe TD; Salganik M; Pintilie DG; Petersen BE
    Lab Invest; 2009 Sep; 89(9):1032-42. PubMed ID: 19581879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
    Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
    Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
    Chou JY; Zingone A; Pan CJ
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of glycogen storage disease type 1a in a mouse model by gene therapy.
    Zingone A; Hiraiwa H; Pan CJ; Lin B; Chen H; Ward JM; Chou JY
    J Biol Chem; 2000 Jan; 275(2):828-32. PubMed ID: 10625614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
    Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
    Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa).
    Farah BL; Sinha RA; Wu Y; Singh BK; Lim A; Hirayama M; Landau DJ; Bay BH; Koeberl DD; Yen PM
    Sci Rep; 2017 Mar; 7():44408. PubMed ID: 28317891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
    Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
    Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
    Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
    Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
    Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
    Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
    Jauze L; Monteillet L; Mithieux G; Rajas F; Ronzitti G
    Hum Gene Ther; 2019 Oct; 30(10):1263-1273. PubMed ID: 31319709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
    Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
    Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.
    Brooks ED; Little D; Arumugam R; Sun B; Curtis S; Demaster A; Maranzano M; Jackson MW; Kishnani P; Freemark MS; Koeberl DD
    Mol Genet Metab; 2013 Jun; 109(2):161-70. PubMed ID: 23623482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
    Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
    Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
    Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
    Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
    Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.
    Cho JH; Kim GY; Pan CJ; Anduaga J; Choi EJ; Mansfield BC; Chou JY
    PLoS Genet; 2017 May; 13(5):e1006819. PubMed ID: 28558013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.